NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ANNX Stock Alerts $7.17 -0.64 (-8.19%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$7.03▼$8.2650-Day Range$4.03▼$7.8152-Week Range$1.57▼$8.40Volume4.06 million shsAverage Volume1.52 million shsMarket Capitalization$381.73 millionP/E RatioN/ADividend YieldN/APrice Target$14.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Annexon alerts: Email Address Annexon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.3% Upside$14.14 Price TargetShort InterestHealthy4.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 23 Articles This WeekInsider TradingSelling Shares$49,514 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.65) to ($1.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.54 out of 5 starsMedical Sector314th out of 938 stocksPharmaceutical Preparations Industry142nd out of 432 stocks 4.5 Analyst's Opinion Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.14, Annexon has a forecasted upside of 97.3% from its current price of $7.17.Amount of Analyst CoverageAnnexon has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.68% of the outstanding shares of Annexon have been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annexon has recently increased by 27.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANNX. Previous Next 3.0 News and Social Media Coverage News SentimentAnnexon has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Annexon this week, compared to 2 articles on an average week.Search Interest52 people have searched for ANNX on MarketBeat in the last 30 days. This is an increase of 2,500% compared to the previous 30 days.MarketBeat Follows12 people have added Annexon to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,514.00 in company stock.Percentage Held by Insiders19.11% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annexon are expected to grow in the coming year, from ($1.65) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Annexon Stock (NASDAQ:ANNX)Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More ANNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANNX Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Price Target Increased to $10.00 by Analysts at Bank of AmericaMarch 29, 2024 | americanbankingnews.comHC Wainwright Weighs in on Annexon, Inc.'s Q1 2024 Earnings (NASDAQ:ANNX)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | markets.businessinsider.comAnticipating Growth: Positive Outlook for Annexon Biosciences Amid Upcoming Clinical Trials and New Data ReadoutsMarch 28, 2024 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Price Target Raised to $12.00 at Wells Fargo & CompanyMarch 28, 2024 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Receives Buy Rating from HC WainwrightMarch 28, 2024 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Receives Buy Rating from Needham & Company LLCMarch 28, 2024 | americanbankingnews.comAnnexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Buy" from AnalystsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 27, 2024 | finanznachrichten.deAnnexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated MilestonesMarch 27, 2024 | markets.businessinsider.comAnnexon Biosciences (ANNX) Receives a Buy from TD CowenMarch 26, 2024 | globenewswire.comAnnexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated MilestonesMarch 18, 2024 | globenewswire.comAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)March 16, 2024 | ca.finance.yahoo.comANNX Jul 2024 7.500 putMarch 16, 2024 | ca.finance.yahoo.comANNX Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comANNX Apr 2024 7.500 putMarch 16, 2024 | finance.yahoo.comNational group to cut realtor commissions, make home-buying more affordableMarch 15, 2024 | finance.yahoo.comCannabis Grower Ascend Seeks Private Loan to Refinance DebtMarch 13, 2024 | seekingalpha.comHRTX, LUNA and ARQ among mid-day moversMarch 7, 2024 | finance.yahoo.comANNX Mar 2024 10.000 putMarch 2, 2024 | msn.comJP Morgan Upgrades Annexon (ANNX)February 27, 2024 | globenewswire.comAnnexon Biosciences to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comAnnexon Stock (NASDAQ:ANNX), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comAnnexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic ApproachFebruary 21, 2024 | globenewswire.comAnnexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic ApproachFebruary 20, 2024 | globenewswire.comAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)February 18, 2024 | finance.yahoo.comANNX Mar 2024 5.000 callSee More Headlines Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANNX CUSIPN/A CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees76Year FoundedN/APrice Target and Rating Average Stock Price Target$14.14 High Stock Price Target$30.00 Low Stock Price Target$7.00 Potential Upside/Downside+89.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-72.38% Return on Assets-57.07% Debt Debt-to-Equity RatioN/A Current Ratio9.85 Quick Ratio9.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book1.48Miscellaneous Outstanding Shares53,240,000Free Float43,065,000Market Cap$381.73 million OptionableOptionable Beta1.10 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Douglas Love Esq. (Age 56)J.D., CEO, President & Director Comp: $921.99kMs. Jennifer Lew (Age 51)Executive VP, CFO & Corporate Secretary Comp: $624.2kMr. Michael Overdorf M.B.A. (Age 54)Executive VP & Chief Business Officer Comp: $580.47kDr. Arnon Rosenthal Ph.D. (Age 68)Founder Dr. Dean R. Artis Ph.D. (Age 63)Chief Scientific Officer & Executive VP Dr. Ted Yednock Ph.D. (Age 66)Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board Comp: $614.6kHenk-Andre Kroon M.D.Senior Vice President of Translational MedicineDr. Jamie Dananberg M.D. (Age 66)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsAmarinNASDAQ:AMRNUroGen PharmaNASDAQ:URGNFibroBiologicsNASDAQ:FBLGPrecigenNASDAQ:PGENADC TherapeuticsNYSE:ADCTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 13,917 shares on 3/11/2024Ownership: 3.584%Goldman Sachs Group Inc.Bought 39,275 shares on 3/1/2024Ownership: 0.535%Virtu Financial LLCBought 48,614 shares on 2/26/2024Ownership: 0.091%Price T Rowe Associates Inc. MDBought 12,509 shares on 2/16/2024Ownership: 0.023%Voya Investment Management LLCSold 2,411 shares on 2/15/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions ANNX Stock Analysis - Frequently Asked Questions Should I buy or sell Annexon stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANNX shares. View ANNX analyst ratings or view top-rated stocks. What is Annexon's stock price target for 2024? 6 equities research analysts have issued 12 month price targets for Annexon's shares. Their ANNX share price targets range from $7.00 to $30.00. On average, they expect the company's stock price to reach $14.14 in the next year. This suggests a possible upside of 97.3% from the stock's current price. View analysts price targets for ANNX or view top-rated stocks among Wall Street analysts. How have ANNX shares performed in 2024? Annexon's stock was trading at $4.54 at the beginning of the year. Since then, ANNX stock has increased by 57.9% and is now trading at $7.17. View the best growth stocks for 2024 here. Are investors shorting Annexon? Annexon saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,490,000 shares, an increase of 27.7% from the February 29th total of 1,950,000 shares. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is currently 1.5 days. View Annexon's Short Interest. When is Annexon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ANNX earnings forecast. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07. What ETFs hold Annexon's stock? ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN). What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE). When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. Who are Annexon's major shareholders? Annexon's stock is owned by a number of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (15.14%), BVF Inc. IL (13.15%), Vanguard Group Inc. (3.58%), Vanguard Group Inc. (3.58%), Vontobel Holding Ltd. (1.22%) and Sectoral Asset Management Inc. (1.22%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Jennifer Lew, Michael Overdorf, Muneer A Satter and Ted Yednock. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANNX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.